JP2007504194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504194A5 JP2007504194A5 JP2006525096A JP2006525096A JP2007504194A5 JP 2007504194 A5 JP2007504194 A5 JP 2007504194A5 JP 2006525096 A JP2006525096 A JP 2006525096A JP 2006525096 A JP2006525096 A JP 2006525096A JP 2007504194 A5 JP2007504194 A5 JP 2007504194A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- defibrotide
- preparation
- active ingredient
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 230000000259 anti-tumor effect Effects 0.000 claims 6
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims 5
- 229960004120 defibrotide Drugs 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims 2
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001714A ITMI20031714A1 (it) | 2003-09-05 | 2003-09-05 | Formazioni ad azione antitumorale. |
| US53934404P | 2004-01-28 | 2004-01-28 | |
| PCT/EP2004/009723 WO2005023273A1 (en) | 2003-09-05 | 2004-08-27 | Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504194A JP2007504194A (ja) | 2007-03-01 |
| JP2007504194A5 true JP2007504194A5 (enExample) | 2007-06-07 |
| JP4671962B2 JP4671962B2 (ja) | 2011-04-20 |
Family
ID=37064585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525096A Expired - Fee Related JP4671962B2 (ja) | 2003-09-05 | 2004-08-27 | デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8551967B2 (enExample) |
| EP (1) | EP1660100B1 (enExample) |
| JP (1) | JP4671962B2 (enExample) |
| KR (1) | KR20060061367A (enExample) |
| CN (1) | CN100490820C (enExample) |
| AT (1) | ATE399558T1 (enExample) |
| AU (1) | AU2004269896B2 (enExample) |
| BR (1) | BRPI0414114A (enExample) |
| CA (1) | CA2537226C (enExample) |
| DE (1) | DE602004014787D1 (enExample) |
| DK (1) | DK1660100T3 (enExample) |
| ES (1) | ES2308223T3 (enExample) |
| IL (1) | IL173785A0 (enExample) |
| IS (1) | IS8334A (enExample) |
| IT (1) | ITMI20031714A1 (enExample) |
| MX (1) | MXPA06002489A (enExample) |
| NO (1) | NO20061402L (enExample) |
| PT (1) | PT1660100E (enExample) |
| RS (1) | RS20060154A (enExample) |
| RU (1) | RU2348413C2 (enExample) |
| UA (1) | UA83500C2 (enExample) |
| WO (1) | WO2005023273A1 (enExample) |
| ZA (1) | ZA200601852B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1855697A2 (en) * | 2005-03-03 | 2007-11-21 | Gentium Spa | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| EP2637672B1 (en) | 2010-11-12 | 2018-08-22 | Gentium S.r.l. | Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd). |
| KR102038357B1 (ko) | 2012-06-22 | 2019-10-31 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| US10380734B2 (en) * | 2017-02-27 | 2019-08-13 | Aniket Bharat Parikh | System, method and computer program product for security analysis of jewelry items |
| EP3661484A1 (en) * | 2017-08-03 | 2020-06-10 | Jazz Pharmaceuticals Ireland Limited | Formulations comprising a nucleic acid in a high concentration |
| WO2019200251A1 (en) | 2018-04-12 | 2019-10-17 | Jazz Pharmaceuticals, Inc. | Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion |
| WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US4853221A (en) * | 1980-11-13 | 1989-08-01 | Warner-Lambert Company | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| DE9202745U1 (de) | 1992-03-02 | 1992-04-30 | Howmedica Gmbh, 2314 Schoenkirchen | Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| CA2259041A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| AU8125098A (en) | 1997-05-30 | 1998-12-30 | Mcgill University | Dna methyltransferase genomic sequences and antisense oligonucleotides |
| US6177545B1 (en) | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| DE19740384A1 (de) | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| AU780454B2 (en) * | 1999-06-03 | 2005-03-24 | Jessie L.S. Au | Methods and compositions for modulating cell proliferation and cell death |
| EP1406930A4 (en) * | 2000-12-29 | 2007-01-10 | Savient Pharmaceuticals Inc | "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF" |
| US6770753B2 (en) | 2001-07-05 | 2004-08-03 | The Trustees Of Columbia University In The City Of New York | Phosphorothioate antisense heparanase oligonucleotides |
| AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
| JP2005527636A (ja) * | 2002-05-31 | 2005-09-15 | クリニクム デア ウニベルジテート レーゲンスブルク | 化学療法中における内皮細胞及び上皮細胞の保護のための方法 |
| WO2004003166A2 (en) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| JP4483581B2 (ja) | 2002-08-06 | 2010-06-16 | 東レ株式会社 | 腎疾患治療又は予防剤及び腎疾患の診断方法 |
| DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| EP1855697A2 (en) | 2005-03-03 | 2007-11-21 | Gentium Spa | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
-
2003
- 2003-09-05 IT IT001714A patent/ITMI20031714A1/it unknown
-
2004
- 2004-08-27 MX MXPA06002489A patent/MXPA06002489A/es active IP Right Grant
- 2004-08-27 BR BRPI0414114-8A patent/BRPI0414114A/pt not_active IP Right Cessation
- 2004-08-27 UA UAA200602374A patent/UA83500C2/uk unknown
- 2004-08-27 ZA ZA200601852A patent/ZA200601852B/en unknown
- 2004-08-27 DE DE602004014787T patent/DE602004014787D1/de not_active Expired - Lifetime
- 2004-08-27 RU RU2006109210/15A patent/RU2348413C2/ru not_active IP Right Cessation
- 2004-08-27 KR KR1020067004451A patent/KR20060061367A/ko not_active Withdrawn
- 2004-08-27 AU AU2004269896A patent/AU2004269896B2/en not_active Ceased
- 2004-08-27 AT AT04764686T patent/ATE399558T1/de active
- 2004-08-27 DK DK04764686T patent/DK1660100T3/da active
- 2004-08-27 ES ES04764686T patent/ES2308223T3/es not_active Expired - Lifetime
- 2004-08-27 PT PT04764686T patent/PT1660100E/pt unknown
- 2004-08-27 CN CNB2004800253315A patent/CN100490820C/zh not_active Expired - Fee Related
- 2004-08-27 RS YUP-2006/0154A patent/RS20060154A/sr unknown
- 2004-08-27 EP EP04764686A patent/EP1660100B1/en not_active Expired - Lifetime
- 2004-08-27 WO PCT/EP2004/009723 patent/WO2005023273A1/en not_active Ceased
- 2004-08-27 CA CA2537226A patent/CA2537226C/en not_active Expired - Fee Related
- 2004-08-27 JP JP2006525096A patent/JP4671962B2/ja not_active Expired - Fee Related
-
2006
- 2006-02-16 IL IL173785A patent/IL173785A0/en unknown
- 2006-02-28 IS IS8334A patent/IS8334A/is unknown
- 2006-03-02 US US11/366,243 patent/US8551967B2/en not_active Expired - Fee Related
- 2006-03-28 NO NO20061402A patent/NO20061402L/no not_active Application Discontinuation
-
2013
- 2013-09-06 US US14/019,674 patent/US20140005256A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7025416B2 (ja) | 好中球減少症を低減させるための組成物および方法 | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| EP4628100A3 (en) | Anti-viral compounds and methods for administration thereof | |
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| CY1106574T1 (el) | Εξαφωσφορικη μυο-ινοσιτολη για τοπικη χρηση | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| WO2009002867A3 (en) | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement | |
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
| WO2009093264A3 (en) | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| AR061668A1 (es) | Jarabes antihistaminicos, estables al almacenamiento, sin azucar | |
| EP4241855A3 (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| JP2008531647A5 (enExample) | ||
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| JP2004534821A5 (enExample) | ||
| JP2010526884A5 (enExample) | ||
| RU2016101152A (ru) | Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств | |
| JP2006527232A5 (enExample) | ||
| AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica |